Zolgensma and Seven Other Products Get CHMP Thumbs Up
Executive Summary
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.
You may also be interested in...
Novartis To Alert EU Doctors About Liver Failure Deaths In Zolgensma Patients
The European Medicines Agency’s pharmacovigilance committee has reviewed the updated advice that EU prescribers will get on enhanced monitoring of spinal muscular atrophy patients treated with Zolgensma following fatal cases of acute liver failure.
Stemline And Karyopharm Want More Time At EMA
A number of companies with marketing applications at the later stages of the EU review process are seeking extra time to address remaining concerns the European Medicines Agency’s drug evaluation committee, the CHMP, has about their filings.
Triple Combination Therapy First For Asthma Among Eight Wins At EMA
Novartis is among a number of companies that this week moved closer to marketing new products across the EU. D&A Pharma has again failed to convince the European Medicines Agency that its alcohol dependence treatment should be approved.